Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222995 · ClinicalTrials.gov registry record · NA
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
A NA study of Skin Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 2,900
- Enrollment target
- 2
- Study locations
NCT07222995: Recruiting NA study of Skin Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT07222995 is a NA study of Skin Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2,900 participants, above the 392-participant average among 40 other Skin Cancer trials with a reported enrollment target (640% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222995, a NA study of Skin Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,900 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.
Primary Outcome
Change in self-reported tanning behavior score from baseline to 6 and 12 months.
Conditions Studied
Interventions
- BEHAVIORAL Precision Prevention Booklet
- BEHAVIORAL Standard Prevention Booklet
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,900 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2030-10-10 |
| Phase | NA |
What NCT07222995 shows while recruiting
NCT07222995 is an interventional study that assigns participants to a tested intervention. Its 2,900 participants enrollment target places it among the larger protocols in the corpus, above the 392-participant average among 40 other Skin Cancer trials with a reported enrollment target (640% higher).
The record links to 1 condition, with Skin Cancer appearing as the primary indexed condition, and to 2 interventions - of which Precision Prevention Booklet is the first listed.
NCT07222995 reports a single indexed study location in Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07222995 about?
NCT07222995 is a clinical study titled "Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs". The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.
What is the current status of trial NCT07222995?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,900 participants. The study started on 2025-10-10. Estimated completion is 2030-10-10.
What conditions does trial NCT07222995 study?
This clinical trial studies the following conditions: Skin Cancer.
What interventions are being tested in trial NCT07222995?
The interventions under investigation include: Precision Prevention Booklet (BEHAVIORAL), Standard Prevention Booklet (BEHAVIORAL).
Who is sponsoring clinical trial NCT07222995?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222995 being conducted?
This trial has 2 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222995's enrollment target sits among peer trials
2,900 2nd of 40 the highest of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
-
DNA Repair Activity in the Skin of Day and Night Shift Workers
RECRUITING · NA
-
Adaptive Symptom Self-Management Immunotherapy Study
RECRUITING · NA
-
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
ACTIVE NOT RECRUITING · NA
-
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI